Approximately 430,000 patients were receiving maintenance dialysis in the United States in 2011
1 . Compared to the general population, atrial fibrillation is far more common 2 and associated with a much higher risk of stroke in the dialysis population 3 . Thus, there is an important need to define and apply strategies to reduce stroke in patients receiving dialysis with atrial fibrillation.
Warfarin for atrial fibrillation is one of the most successful treatments in all of medicine, preventing nearly two-thirds of strokes in the general atrial fibrillation population 4 .
Approximately one-fifth of all strokes are related to atrial fibrillation, and these strokes are more frequently disabling or fatal than strokes associated with other conditions. It is now well established that impaired kidney function is associated with increased risks of stroke and of bleeding associated with the use of anticoagulation 5 . Patients with mild-to-moderate chronic kidney disease and atrial fibrillation experience greater relative and absolute benefits from warfarin therapy 6 . Despite the lack of evidence derived from randomized clinical trials in the dialysis population, Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines published in 2006 7 recommended that warfarin be used as per American Heart
Association guidelines for atrial fibrillation with the caveat that "dialysis patients are at increased risk for bleeding and careful monitoring should accompany intervention."
Since then, several observational studies have questioned the benefit of warfarin for stroke prevention, particularly when balancing the risks of bleeding in this population 8 ki idn dn ney ey ey d d dis is isea ea e s s se a and nd nd a atrial fibrillation experience gr gr g e ea ater relative a and nd n abs bs so ol olute benefits from w war rf rfarin thera apy py 6 . D De e espi pi pite te te t the he he l lac ac ck k of of e ev vide e enc c ce d der r rive ed ed f fro ro om m m ra rand nd ndom miz iz ize ed d c cl li lin ni nica cal l l tr tr ria ia ials ls l i i in n n th h the e d di dial al alys ys ysis is i p p pop op opul ul u at ati io on n, n, K K Kid idne ne n y y Di Di D se se seas as ase e: e: I Imp mp mpro ro rov v ving ng ng G Gl Glo o obal al a O O Ou ut utco o ome me mes s (K (K (KD D DIGO GO GO) ) ) cl cl clin inic ic ica al al p p pra ract ct c ic ice e guidelines p pub ub bli li ish sh hed ed ed i in n n 20 2006 06 06 7 7 7 rec ec ecom om omme me end nd nded ed d t t tha ha hat t t wa wa warf rf r ar ar rin in in b b be e e us us used ed e a a as s pe pe per r r Am Am Amer er eric ic ican an an H H Heart warfarin was associated with nearly twice the risk of stroke after adjustment for comorbidities 9 .
A third study showed a higher risk of hemorrhagic stroke and no lower risk of ischemic stroke with warfarin in hemodialysis using claims data from Medicare patients augmented with the United States Renal Data System (USRDS) 10 . While another study from Denmark found a lower risk of stroke with warfarin use for patients with atrial fibrillation receiving dialysis 3 and data included in the 2013 USRDS Annual Data Report found a lower risk of stroke in warfarintreated patients, there was enough uncertainty that the KDIGO summary in 2011 changed the recommendation to not advise warfarin for stroke prevention in end stage renal disease 11 . This group highlighted the need for clinical trials of anticoagulants in advanced chronic kidney disease (CKD) (stage 4 and 5, including persons on dialysis) as an area for future research. The
Canadian Cardiovascular Society Atrial Fibrillation Guidelines, likewise, no longer recommend warfarin for atrial fibrillation for patients on dialysis 12 and called for randomized trials.
In this issue of Circulation, Shah and coauthors have provided additional data to inform this debate 13 . The authors identified patients admitted to hospitals in Ontario and Quebec with atrial fibrillation and analyzed outcomes according to subsequent use of warfarin and according to dialysis status. Among the 1626 patients on dialysis, nearly half were prescribed warfarin.
The authors found no reduction in stroke risk associated with warfarin use after adjusting for other predictors (hazard ratio 1.14, 95% confidence interval (95% CI) 0.78 to 1.67), but a significantly higher risk of bleeding (hazard ratio 1.44, 95% CI 1.13 to 1.85), similar to findings reported by Winkelmayer et al 10 . The study by Shah et al included a broad population base, adjusted for key determinants of stroke and bleeding (components of the CHADS2 and HAS-BLED scores), and employed propensity score adjustment to address confounding by indication.
But even with careful adjustment, observational studies are limited by the effects of unmeasured disease (CKD) (stage 4 and 5, including persons on dialysis) as an area for future re e res e e ea ea arc c rch. h. h Th The
Canadian Cardiovascular Society Atrial Fibrillation Guidelines, likewise, no longer recommend wa warf rf rfar ar rin in in f f for or or a a atria ia al l l fi fibrillation for patients on dia aly ly lysi i is 12 and called d fo f f r ra ra and nd ndomized trials. While the balance of risks and benefits of warfarin appear favorable in patients with mild-to-moderate CKD, too few patients with advanced CKD have been included in randomized trials, including no patients with creatinine clearance of less than 25 ml/min in the trials of direct acting oral anticoagulants in atrial fibrillation [14] [15] [16] [17] . A potential role of the direct acting oral anticoagulants in patients with advanced CKD is supported by data showing consistent benefits compared to warfarin in patients with moderate CKD [14] [15] [16] [17] [18] . Whether another strategy to prevent stroke, left atrial occluder devices 19 , is appropriate for the dialysis population also requires further study. Trials of statins have shown us that the dialysis population is sufficiently different that treatment effects may fundamentally differ from those observed in the general population 20 .
Where are we in understanding the effect of warfarin for atrial fibrillation in dialysis patients? We have compelling evidence of benefit of warfarin for stroke prevention in atrial fibrillation and evidence that the benefit is as great or greater in patients with moderate renal impairment ( Table 1) . At the same time we have reasonably consistent findings from observational studies that there are similar or higher stroke rates and higher bleeding rates with warfarin in the dialysis population. Given the unreliability of using observational studies to estimate treatment effects, the truth may be that oral anticoagulation provides important benefit.
But the study by Shah et al adds to the evidence that it is also possible that warfarin is harmful in this setting. It is ironic that we are routinely treating many patients with renal disease and atrial anticoagulants in patients with advanced CKD is supported by data showing con ns s sist st ten ent t be be bene ne nefi f fit ts compared to warfarin in patients with moderate CKD [14] [15] [16] [17] [18] . Whether another strategy to prevent t tro ro oke ke ke, , l le left ft ft a atr tr t ial l o o oc cc ccluder devices 19 , is appropria a ate te t f for the dialysis is s pop pul ul ula a ation also requires f fu urt t th her study. Tr Tr Tria a als s o o of st s stat at atin in ns s s ha have ve ve s sh ho how w wn u u us tha at t t th he d di ia ialy ly ysi is s p po op pu pula lati ti tion n n is s s s su uf uffi fici ci c en en entl tl tly y di di diff f ffer er ren e t h hat at at t tre re reat atme me ment nt n e ef ff ffec ec cts ts m may ay a fun un nda da dame me men nt nta al ally y y d d di if iffe fe er r r fr fr rom m m t t tho ho ose se se o obs bs bser er rve ve ed d d in in n t th he he g g gen en ner era al al p p pop op pul ul lat atio io on n 2 20 .
Wher re e e ar ar a e e e we we w i i in n n un n nde de ders rsta ta tand nd ndin in ing g g th th the e e ef ef effe fe f ct ct c o o of f wa wa w rf rf rfar ar arin in in f f for or or a atr r ria ia ial l l fi fi fibr br bril il illa lati ti tion on on i in n n di d d alysis RCT=randomized clinical trial; CKD = chronic kidney disease; AF = atrial fibrillation; ESRD = = e e end nd d sta ta age ge ge r r ren en enal a al disease
